Immuneering Co. (NASDAQ:IMRX - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,290,000 shares, a growth of 41.4% from the November 30th total of 1,620,000 shares. Approximately 10.2% of the company's shares are short sold. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is currently 2.0 days.
Analysts Set New Price Targets
Several analysts recently weighed in on the stock. Morgan Stanley downgraded shares of Immuneering from an "equal weight" rating to an "underweight" rating in a report on Friday, December 13th. Chardan Capital restated a "buy" rating and set a $13.00 price target on shares of Immuneering in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price objective on shares of Immuneering in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $12.80.
Read Our Latest Analysis on IMRX
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Corsair Capital Management L.P. purchased a new position in shares of Immuneering in the 3rd quarter valued at about $25,000. Vontobel Holding Ltd. acquired a new stake in Immuneering in the third quarter valued at approximately $25,000. XTX Topco Ltd lifted its stake in Immuneering by 37.3% in the second quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock worth $44,000 after acquiring an additional 9,274 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Immuneering during the 2nd quarter worth approximately $44,000. Finally, Tidemark LLC purchased a new stake in shares of Immuneering in the 3rd quarter valued at approximately $129,000. 67.65% of the stock is owned by institutional investors and hedge funds.
Immuneering Stock Performance
Shares of Immuneering stock traded down $0.08 during trading hours on Monday, reaching $2.25. 323,886 shares of the company were exchanged, compared to its average volume of 2,080,029. The firm has a market cap of $69.86 million, a PE ratio of -1.14 and a beta of -0.33. Immuneering has a 1 year low of $1.00 and a 1 year high of $7.68. The stock's fifty day moving average is $2.01 and its 200 day moving average is $1.73.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Further Reading
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
